Aion Therapeutic Inc. (AION.CN)
| Previous Close | 0.0250 |
| Open | 0.0200 |
| Bid | 0.0200 x N/A |
| Ask | 0.0250 x N/A |
| Day's Range | 0.0200 - 0.0250 |
| 52 Week Range | 0.0150 - 0.1900 |
| Volume | |
| Avg. Volume | 286,487 |
| Market Cap | 3.545M |
| Beta (5Y Monthly) | 0.92 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0670 |
| Earnings Date | Sep. 30, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Aion Therapeutic Files Financials
Toronto, Ontario--(Newsfile Corp. - November 2, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").Management of the Company has been subject to a management cease trade order (the "MCTO") in respect of the securities of the Company issued by the applicable securities ...
- CNW Group
Aion Therapeutic Provides Default Status Update
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that further to its press releases of September 14, 2021 and September 28, 2021, the Company is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").
- CNW Group
Aion Therapeutic Provides Notice of Default
Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces that it anticipates being late in filing its audited annual financial statements (the "Annual Financial Statements") and related management discussion and analysis ("MD&A") for the year ended April 30, 2021, by the prescribed deadline of August 30, 2021, and its interim financial statements (the "Interim Financial Statements") and related MD&A for the interim period ended July 31, 2021, by the prescribed deadline o
